The food and drug administration (FDA) has already approved the wide use of G-CSF and granulocyte/macrophage-colony-stimulating factor (GM-CSF), benefiting 20 million people worldwide and saving USD 5 billion per year annually in the USA, for the treatment of congenital and acquired neutropenias where GM-CSF is typically recommended for neutropenia associated with stem cell transplantation as it also promotes antigen presenting cells function [13]. This evidence concerns the gene CSF3 and Decreased total neutrophil count.